View Financial HealthSynlogic 배당 및 자사주 매입배당 기준 점검 0/6Synlogic 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.1%자사주 매입 수익률총 주주 수익률-0.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 23Synlogic, Inc.(OTCPK:SYBX) dropped from S&P TMI IndexSynlogic, Inc.(OTCPK:SYBX) dropped from S&P TMI Index공시 • Jan 22Synlogic, Inc.(OTCPK:SYBX) dropped from NASDAQ Composite IndexSynlogic, Inc. has been dropped from the NASDAQ Composite Index .New Risk • Jan 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$6.55m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (US$6.55m market cap).공시 • Nov 27Synlogic, Inc. Receives Notice of Nasdaq Delisting Due to Public Shell Status and Operational DeclineOn November 21, 2025, Synlogic, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC that stated the Staff’s belief that the Company is a “public shell” and that, therefore, the continued listing of its securities is no longer warranted in the view of the Staff. In the Notice, the Staff explained that it based this belief on its review of the Company’s public disclosures and materials submitted to the Staff by the company. In addition, the Staff noted its belief is supported by the Company’s lack of revenue generating assets and the substantial reduction in employees and operations since February 2024. The Staff also considered the company’s quarterly reports on Forms 10-Q filed on May 8, 2025, August 7, 2025, and November 13, 2025, respectively, which indicated that the Company has not generated any revenue for the nine months ended 2025 and that the company had research and development expenses of only $16,000. The Notice further advised that, unless the Company timely requests a hearing before a Hearings Panel, it would be subject to suspension/delisting. The company disagrees with the Staff’s view regarding the Company’s status as a “public shell” and, accordingly, intends to timely request a hearing. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period that may be granted by the Panel following the hearing. However, there can be no assurance that the Company’s hearing will be successful, or that, if successful, the Company will be able to maintain compliance with all applicable listing criteria.공시 • Nov 14Synlogic, Inc., Annual General Meeting, Dec 15, 2025Synlogic, Inc., Annual General Meeting, Dec 15, 2025.Valuation Update With 7 Day Price Move • Jul 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.51, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total loss to shareholders of 91% over the past three years.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 28%After last week's 28% share price gain to US$1.52, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 91% over the past three years.Reported Earnings • Mar 08Full year 2024 earnings released: US$1.92 loss per share (vs US$8.81 loss in FY 2023)Full year 2024 results: US$1.92 loss per share (improved from US$8.81 loss in FY 2023). Net loss: US$23.4m (loss narrowed 59% from FY 2023). Revenue is expected to decline by 150% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 12%.공시 • Feb 22Synlogic, Inc. Announces Resignation of Michael Heffernan as A Member of the Board of Directors and as A Member of the Audit Committee and Nominating and Governance CommitteeSynlogic, Inc. announced the resignation of Michael Heffernan as a member of the board of directors and as a member of the audit committee and nominating and governance committee of the Board, effective immediately.Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023)Third quarter 2024 results: US$0.01 loss per share (improved from US$2.57 loss in 3Q 2023). Net loss: US$117.0k (loss narrowed 99% from 3Q 2023). Revenue is expected to decline by 118% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 20%.공시 • Nov 07Synlogic, Inc., Annual General Meeting, Dec 04, 2024Synlogic, Inc., Annual General Meeting, Dec 04, 2024.New Risk • Sep 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Shareholders have been substantially diluted in the past year (156% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.4m net loss in 2 years). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$17.3m market cap).New Risk • Aug 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$49m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Shareholders have been substantially diluted in the past year (156% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.4m net loss in 2 years). Share price has been volatile over the past 3 months (9.3% average weekly change). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$16.4m market cap).Reported Earnings • Aug 09Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.17 (up from US$3.21 loss in 2Q 2023). Net income: US$2.01m (up US$17.1m from 2Q 2023). Revenue is expected to decline by 200% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 17%.New Risk • Jun 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$46m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$46m free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (157% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$36m net loss next year). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$19.0m market cap).Reported Earnings • May 15First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)First quarter 2024 results: US$2.60 loss per share. Revenue: US$8.0k (down 95% from 1Q 2023). Net loss: US$31.6m (loss widened 102% from 1Q 2023). Revenue is expected to decline by 188% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 20%.공시 • Feb 18Cable Car Capital Discloses its Views on SynlogicOn February 16, 2024, Cable Car Capital LLC announced that it wishes to express condolences on the recent disappointing clinical outcome while commending Synlogic, Inc.’s Board of Directors on its swift response. Cable Car Capital stated that it intends to provide input into the announced strategic alternatives review process.공시 • Feb 09+ 3 more updatesSynlogic, Inc. Announces Departure of Aoife Brennan as PresidentSynlogic, Inc. announced that Dr. Aoife Brennan is also departing as President and Chief Executive Officer as part of the reduction, and stepping down from the Board of Directors.공시 • Feb 03Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical HomocystinuriaSynlogic, Inc. announced the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU). Among findings outlined in the manuscript, SYNB1353 efficiently degraded both dietary and entero-recirculating methionine to prevent its absorption and subsequent conversion to homocysteine in preclinical models, suggesting that SYNB1353 should result in lowering of plasma homocysteine levels in HCU patients. In addition, in results from the clinical study in healthy volunteers, SYNB1353 was generally well-tolerated and adverse events were mild to moderate, transient, and predominantly gastrointestinal in nature. The proportion of subjects reporting gastrointestinal events were similar for the SYNB1353 and placebo cohorts (36.4% and 37.5%, respectively).공시 • Nov 18Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023Synlogic, Inc. announced the appointment of Michael Jensen, Chief Financial Officer of Synlogic, Inc. (the “Company”) resigned from his role as Chief Financial Officer of the Company, effective December 1, 2023 (the “Departure Date”). Mr. Jensen’s departure is not the result of any disagreement with the Company on any matter related to the Company's operations, policies or procedures. In connection with Mr. Jensen’s resignation, on November 13, 2023, Mr. Jensen and the Company entered into a voluntary separation agreement and release of claims (the “Separation Agreement”). Pursuant to the terms of the Separation Agreement, Mr. Jensen will resign as an officer and employee of the Company effective at the close of business on December 1, 2023. Mr. Jensen will assist the Company through the Departure Date in the transition of work in connection with his duties as Chief Financial Officer of the Company. In consideration for, among other things, his compliance with certain restrictive covenants, including customary non-compete and non-solicitation covenants, and a typical release of claims, Mr. Jensen shall receive a lump-sum payment equal to $149,178 in lieu of any other bonus that Mr. Jensen would be eligible for the fiscal year ending December 31, 2023. Mr. Jensen is also entitled to continued health insurance coverage for up to six months following the Departure Date. The foregoing description of the material terms of the Separation Agreement is qualified in its entirety by the full text of the Separation Agreement, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the year ending December 31, 2023.Reported Earnings • Nov 11Third quarter 2023 earnings released: US$2.57 loss per share (vs US$3.73 loss in 3Q 2022)Third quarter 2023 results: US$2.57 loss per share (improved from US$3.73 loss in 3Q 2022). Net loss: US$12.1m (loss narrowed 33% from 3Q 2022). Revenue is forecast to grow 75% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the United Kingdom.공시 • Jun 07Synlogic, Inc. Announces Implementation of Reduction in WorkforceOn June 5, 2023, Synlogic, Inc. announced that it is implementing a reduction in workforce designed to focus resources on advancing the Company’s clinical stage programs and research activities that support the current clinical pipeline and its ongoing collaboration with Roche. The realignment is estimated to reduce the Company’s workforce by approximately 21%. The Company expects to complete substantially all of the reduction in workforce by the end of the fiscal quarter ending June 30, 2023. The Company estimates that it will incur approximately $0.9 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The Company communicated the workforce reduction on May 31, 2023 and expects the majority of the costs associated with the strategic realignment to be incurred during the second quarter ending June 30, 2023 and the third quarter ending September 30, 2023. The charges the Company expects to incur in connection with this reduction in workforce are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions.공시 • Jun 06Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of PhenylketonuriaSynlogic, Inc. announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU). Synpheny-3 is a randomized, placebo-controlled, global, multi-center, pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of SYNB1934 as a treatment for PKU. The final trial design incorporates feedback from global regulatory agencies including the U.S. Food and Drug Administration (FDA). The global study will enroll approximately 150 patients with plasma phenylalanine (Phe) levels at baseline of >360 µM. Synpheny-3 will include patients ages 18 years and older; an initial subset of data from patients in Part 1 will be used to assess the opportunity to lower the age of enrollment to 12 years of age. Study participants may follow their usual diet while participating in the trial. Synpheny-3 is expected to be conducted at approximately 30 clinical sites across the United States, Canada, Germany, Denmark, Israel, Turkey and Georgia. The study has been designed for patient convenience, and offers opportunities to participate in person, or in a virtual or hybrid format. The study consists of three parts: Part 1 is a run-in period, enabling individualized titration across three potential dose levels (3x1011, 6x1011 and 1x1012), with patients spending a minimum of three weeks at each dose. Part 2 of the trial is a four-week, placebo-controlled, randomized withdrawal that will be used to assess the primary endpoint: change in levels of plasma Phe, with a primary analysis conducted among responders from Part 1. The definition for responders is a reduction in plasma Phe from baseline of >20%. Part 3 is an open-label extension that may extend for up to three years.공시 • Jan 20Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for PhenylketonuriaSynlogic, Inc. announced that SYNB1934 was granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for the potential treatment of phenylketonuria (PKU). Synlogic also received RPDD for SYNB1353 for the potential treatment of homocystinuria (HCU) in December 2022. The FDA grants RPDD for serious and life-threatening diseases that primarily affect individuals from birth to 18 years old and fewer than 200,000 persons in the U.S. RPDD means that the sponsor may be entitled to receive a pediatric priority review voucher (pPRV) if the drug is initially approved for that rare childhood disease.공시 • Jan 04Synlogic, Inc. Appoints Dave Hava as Head of Research and DevelopmentSynlogic, Inc. announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. Through the integration of the company's research and development teams, Dr. Hava will oversee the advancement of clinical stage programs in addition to progressing their collaboration with Roche and select preclinical programs. Since joining Synlogic in 2020, Dr. Hava has served as Chief Scientific Officer and led the research department with responsibilities including the advancement of SYNB1353 into clinical development as a potential treatment of homocystinuria (HCU) and SYNB2081 into IND-enabling studies as a potential treatment for gout; the oversight of research collaborations with Ginkgo Bioworks and Roche; and leadership of Synlogic's preclinical activities in immunology. Dr. Hava joined Synlogic with 16 years of experience in the pharmaceutical industry leading platform and drug development programs, with roles including Chief Scientific Officer at Metera Pharmaceuticals and Pulmatrix Inc., where he led research, development, and clinical teams.Board Change • Oct 13High number of new directorsIndependent Director Lisa Kelly-Croswell was the last director to join the board, commencing their role in 2021.Board Change • Jul 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Lisa Kelly-Croswell was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Executive Departure • Jun 15Independent Director Chau Khuong has left the companyOn the 10th of June, Chau Khuong's tenure as Independent Director ended after 3.8 years in the role. We don't have any record of a personal shareholding under Chau's name. Chau is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 0A8U 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 0A8U 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Synlogic 배당 수익률 vs 시장0A8U의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (0A8U)n/a시장 하위 25% (GB)2.2%시장 상위 25% (GB)5.7%업계 평균 (Biotechs)2.4%분석가 예측 (0A8U) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 0A8U 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 0A8U 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 0A8U 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 0A8U 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YGB 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/20 23:09종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Synlogic, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Christopher HowertonJefferies LLCJoseph SchwartzLeerink Partners LLCMark BreidenbachOppenheimer & Co. Inc.2명의 분석가 더 보기
공시 • Jan 23Synlogic, Inc.(OTCPK:SYBX) dropped from S&P TMI IndexSynlogic, Inc.(OTCPK:SYBX) dropped from S&P TMI Index
공시 • Jan 22Synlogic, Inc.(OTCPK:SYBX) dropped from NASDAQ Composite IndexSynlogic, Inc. has been dropped from the NASDAQ Composite Index .
New Risk • Jan 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$6.55m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (US$6.55m market cap).
공시 • Nov 27Synlogic, Inc. Receives Notice of Nasdaq Delisting Due to Public Shell Status and Operational DeclineOn November 21, 2025, Synlogic, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC that stated the Staff’s belief that the Company is a “public shell” and that, therefore, the continued listing of its securities is no longer warranted in the view of the Staff. In the Notice, the Staff explained that it based this belief on its review of the Company’s public disclosures and materials submitted to the Staff by the company. In addition, the Staff noted its belief is supported by the Company’s lack of revenue generating assets and the substantial reduction in employees and operations since February 2024. The Staff also considered the company’s quarterly reports on Forms 10-Q filed on May 8, 2025, August 7, 2025, and November 13, 2025, respectively, which indicated that the Company has not generated any revenue for the nine months ended 2025 and that the company had research and development expenses of only $16,000. The Notice further advised that, unless the Company timely requests a hearing before a Hearings Panel, it would be subject to suspension/delisting. The company disagrees with the Staff’s view regarding the Company’s status as a “public shell” and, accordingly, intends to timely request a hearing. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period that may be granted by the Panel following the hearing. However, there can be no assurance that the Company’s hearing will be successful, or that, if successful, the Company will be able to maintain compliance with all applicable listing criteria.
공시 • Nov 14Synlogic, Inc., Annual General Meeting, Dec 15, 2025Synlogic, Inc., Annual General Meeting, Dec 15, 2025.
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$1.51, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total loss to shareholders of 91% over the past three years.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 28%After last week's 28% share price gain to US$1.52, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total loss to shareholders of 91% over the past three years.
Reported Earnings • Mar 08Full year 2024 earnings released: US$1.92 loss per share (vs US$8.81 loss in FY 2023)Full year 2024 results: US$1.92 loss per share (improved from US$8.81 loss in FY 2023). Net loss: US$23.4m (loss narrowed 59% from FY 2023). Revenue is expected to decline by 150% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 12%.
공시 • Feb 22Synlogic, Inc. Announces Resignation of Michael Heffernan as A Member of the Board of Directors and as A Member of the Audit Committee and Nominating and Governance CommitteeSynlogic, Inc. announced the resignation of Michael Heffernan as a member of the board of directors and as a member of the audit committee and nominating and governance committee of the Board, effective immediately.
Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023)Third quarter 2024 results: US$0.01 loss per share (improved from US$2.57 loss in 3Q 2023). Net loss: US$117.0k (loss narrowed 99% from 3Q 2023). Revenue is expected to decline by 118% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 20%.
공시 • Nov 07Synlogic, Inc., Annual General Meeting, Dec 04, 2024Synlogic, Inc., Annual General Meeting, Dec 04, 2024.
New Risk • Sep 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Shareholders have been substantially diluted in the past year (156% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.4m net loss in 2 years). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$17.3m market cap).
New Risk • Aug 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$49m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$49m free cash flow). Shareholders have been substantially diluted in the past year (156% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$4.4m net loss in 2 years). Share price has been volatile over the past 3 months (9.3% average weekly change). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$16.4m market cap).
Reported Earnings • Aug 09Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.17 (up from US$3.21 loss in 2Q 2023). Net income: US$2.01m (up US$17.1m from 2Q 2023). Revenue is expected to decline by 200% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 17%.
New Risk • Jun 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$46m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$46m free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (157% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$36m net loss next year). Revenue is less than US$5m (US$3.2m revenue). Market cap is less than US$100m (US$19.0m market cap).
Reported Earnings • May 15First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)First quarter 2024 results: US$2.60 loss per share. Revenue: US$8.0k (down 95% from 1Q 2023). Net loss: US$31.6m (loss widened 102% from 1Q 2023). Revenue is expected to decline by 188% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the United Kingdom are expected to grow by 20%.
공시 • Feb 18Cable Car Capital Discloses its Views on SynlogicOn February 16, 2024, Cable Car Capital LLC announced that it wishes to express condolences on the recent disappointing clinical outcome while commending Synlogic, Inc.’s Board of Directors on its swift response. Cable Car Capital stated that it intends to provide input into the announced strategic alternatives review process.
공시 • Feb 09+ 3 more updatesSynlogic, Inc. Announces Departure of Aoife Brennan as PresidentSynlogic, Inc. announced that Dr. Aoife Brennan is also departing as President and Chief Executive Officer as part of the reduction, and stepping down from the Board of Directors.
공시 • Feb 03Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical HomocystinuriaSynlogic, Inc. announced the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU). Among findings outlined in the manuscript, SYNB1353 efficiently degraded both dietary and entero-recirculating methionine to prevent its absorption and subsequent conversion to homocysteine in preclinical models, suggesting that SYNB1353 should result in lowering of plasma homocysteine levels in HCU patients. In addition, in results from the clinical study in healthy volunteers, SYNB1353 was generally well-tolerated and adverse events were mild to moderate, transient, and predominantly gastrointestinal in nature. The proportion of subjects reporting gastrointestinal events were similar for the SYNB1353 and placebo cohorts (36.4% and 37.5%, respectively).
공시 • Nov 18Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023Synlogic, Inc. announced the appointment of Michael Jensen, Chief Financial Officer of Synlogic, Inc. (the “Company”) resigned from his role as Chief Financial Officer of the Company, effective December 1, 2023 (the “Departure Date”). Mr. Jensen’s departure is not the result of any disagreement with the Company on any matter related to the Company's operations, policies or procedures. In connection with Mr. Jensen’s resignation, on November 13, 2023, Mr. Jensen and the Company entered into a voluntary separation agreement and release of claims (the “Separation Agreement”). Pursuant to the terms of the Separation Agreement, Mr. Jensen will resign as an officer and employee of the Company effective at the close of business on December 1, 2023. Mr. Jensen will assist the Company through the Departure Date in the transition of work in connection with his duties as Chief Financial Officer of the Company. In consideration for, among other things, his compliance with certain restrictive covenants, including customary non-compete and non-solicitation covenants, and a typical release of claims, Mr. Jensen shall receive a lump-sum payment equal to $149,178 in lieu of any other bonus that Mr. Jensen would be eligible for the fiscal year ending December 31, 2023. Mr. Jensen is also entitled to continued health insurance coverage for up to six months following the Departure Date. The foregoing description of the material terms of the Separation Agreement is qualified in its entirety by the full text of the Separation Agreement, a copy of which will be filed as an exhibit to the Company’s annual report on Form 10-K for the year ending December 31, 2023.
Reported Earnings • Nov 11Third quarter 2023 earnings released: US$2.57 loss per share (vs US$3.73 loss in 3Q 2022)Third quarter 2023 results: US$2.57 loss per share (improved from US$3.73 loss in 3Q 2022). Net loss: US$12.1m (loss narrowed 33% from 3Q 2022). Revenue is forecast to grow 75% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the United Kingdom.
공시 • Jun 07Synlogic, Inc. Announces Implementation of Reduction in WorkforceOn June 5, 2023, Synlogic, Inc. announced that it is implementing a reduction in workforce designed to focus resources on advancing the Company’s clinical stage programs and research activities that support the current clinical pipeline and its ongoing collaboration with Roche. The realignment is estimated to reduce the Company’s workforce by approximately 21%. The Company expects to complete substantially all of the reduction in workforce by the end of the fiscal quarter ending June 30, 2023. The Company estimates that it will incur approximately $0.9 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The Company communicated the workforce reduction on May 31, 2023 and expects the majority of the costs associated with the strategic realignment to be incurred during the second quarter ending June 30, 2023 and the third quarter ending September 30, 2023. The charges the Company expects to incur in connection with this reduction in workforce are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions.
공시 • Jun 06Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of PhenylketonuriaSynlogic, Inc. announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU). Synpheny-3 is a randomized, placebo-controlled, global, multi-center, pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of SYNB1934 as a treatment for PKU. The final trial design incorporates feedback from global regulatory agencies including the U.S. Food and Drug Administration (FDA). The global study will enroll approximately 150 patients with plasma phenylalanine (Phe) levels at baseline of >360 µM. Synpheny-3 will include patients ages 18 years and older; an initial subset of data from patients in Part 1 will be used to assess the opportunity to lower the age of enrollment to 12 years of age. Study participants may follow their usual diet while participating in the trial. Synpheny-3 is expected to be conducted at approximately 30 clinical sites across the United States, Canada, Germany, Denmark, Israel, Turkey and Georgia. The study has been designed for patient convenience, and offers opportunities to participate in person, or in a virtual or hybrid format. The study consists of three parts: Part 1 is a run-in period, enabling individualized titration across three potential dose levels (3x1011, 6x1011 and 1x1012), with patients spending a minimum of three weeks at each dose. Part 2 of the trial is a four-week, placebo-controlled, randomized withdrawal that will be used to assess the primary endpoint: change in levels of plasma Phe, with a primary analysis conducted among responders from Part 1. The definition for responders is a reduction in plasma Phe from baseline of >20%. Part 3 is an open-label extension that may extend for up to three years.
공시 • Jan 20Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for PhenylketonuriaSynlogic, Inc. announced that SYNB1934 was granted Rare Pediatric Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA) for the potential treatment of phenylketonuria (PKU). Synlogic also received RPDD for SYNB1353 for the potential treatment of homocystinuria (HCU) in December 2022. The FDA grants RPDD for serious and life-threatening diseases that primarily affect individuals from birth to 18 years old and fewer than 200,000 persons in the U.S. RPDD means that the sponsor may be entitled to receive a pediatric priority review voucher (pPRV) if the drug is initially approved for that rare childhood disease.
공시 • Jan 04Synlogic, Inc. Appoints Dave Hava as Head of Research and DevelopmentSynlogic, Inc. announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. Through the integration of the company's research and development teams, Dr. Hava will oversee the advancement of clinical stage programs in addition to progressing their collaboration with Roche and select preclinical programs. Since joining Synlogic in 2020, Dr. Hava has served as Chief Scientific Officer and led the research department with responsibilities including the advancement of SYNB1353 into clinical development as a potential treatment of homocystinuria (HCU) and SYNB2081 into IND-enabling studies as a potential treatment for gout; the oversight of research collaborations with Ginkgo Bioworks and Roche; and leadership of Synlogic's preclinical activities in immunology. Dr. Hava joined Synlogic with 16 years of experience in the pharmaceutical industry leading platform and drug development programs, with roles including Chief Scientific Officer at Metera Pharmaceuticals and Pulmatrix Inc., where he led research, development, and clinical teams.
Board Change • Oct 13High number of new directorsIndependent Director Lisa Kelly-Croswell was the last director to join the board, commencing their role in 2021.
Board Change • Jul 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Lisa Kelly-Croswell was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Executive Departure • Jun 15Independent Director Chau Khuong has left the companyOn the 10th of June, Chau Khuong's tenure as Independent Director ended after 3.8 years in the role. We don't have any record of a personal shareholding under Chau's name. Chau is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.